Condition

HER2-negative Breast Cancer

ClinicalTrials.gov condition label

Clinical trials138

Recruiting52

Common interventions25

Lead sponsors shown15

Clinical trials

60 shown

A Study of the TheraBionic P1 Device in Breast CancerNCT07218432 · 2026-10-01

Metronomic Oral Paclitaxel Monotherapy for Advanced HER2-Negative Breast Cancer: A Two-Stage Dose-Finding and Expansion StudyNCT07602907 · 2026-08-04

Real-life Evaluation of Endopredict® in Early HR+/HER2- Breast CancerNCT07379918 · 2026-06-28

Real-world Study of SKB264 Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast CancerNCT06993506 · 2026-05-28

CDK4/6 Inhibitors Combined With Endocrine Therapy for Neoadjuvant TreatmentNCT07366112 · 2026-04-20

A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Lobular Breast CancerNCT07483307 · 2026-03-13

A Ph II Study of the TheraBionic P1 Device in Subjects With Hormone Positive Breast CancerNCT07227831 · 2026-01-16

Phase III Study to Evaluate the Safety, Efficacy, and Impact on Quality of Life of Capivasertib Alongside Standard-of-care Endocrine Treatment in Patients With HR+/HER2- Advanced Breast Cancer and Progression on Prior Endocrine-based TreatmentNCT07281833 · 2025-11-27

ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast CancerNCT07198724 · 2025-11-17

Breast Re-irradiation After Second Ipsilateral LumpectomyNCT06867484 · 2025-10-27

Prospective Registry of ADC as First- and Second-line Treatment for Breast CancerNCT06774027 · 2025-10-08

ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast CancerNCT06970912 · 2025-08-01

A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory CarcinomasNCT06999187 · 2025-06-03

NearWave Optical Molecular MonitoringNCT06744465 · 2025-03-07

BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast CancerNCT06756932 · 2025-02-04

Adherence to Aromatase Inhibitors ± Abemaciclib Treatment in Patients With Early-stage HER2-negative Breast CancerNCT06650423 · 2025-01-05

Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.NCT06382948 · 2024-12-05

A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast CancerNCT06678269 · 2024-11-15

TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXdNCT06533826 · 2024-10-29

Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast CancerNCT06649331 · 2024-10-21

Study to Evaluate Biomarkers and Safety of Dapagliflozin Concomitant With Neoadjuvant TherapyNCT05989347 · 2024-10-15

Organoid-based Functional Precision Therapy for Advanced Breast CancerNCT06102824 · 2024-10-01

Neoadjuvant Treatment of gBRCA-Mutated HER2-Negative Breast Cancer With HRS-1167 and Famitinib ± CamrelizumabNCT06516289 · 2024-09-30

Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast CancerNCT06488378 · 2024-08-13

Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.NCT06590857 · 2024-07-19

DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Breast Cancer PatientsNCT06388122 · 2024-04-30

DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEsNCT06176261 · 2024-01-08

Intrathecal Chemotherapy Through Ommaya Reservoir Upon Her-2 Negative Breast Cancer With Leptomeningeal MetastasisNCT06230055 · 2024-01-05

Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)NCT05512364 · 2023-12-15

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid TumorsNCT06120283 · 2023-12-01

PRE-ISPY Phase I/II Oncology Platform ProgramNCT05868226 · 2023-02-15

OFS in Premenopausal Node+ Breast Cancer With Low Genomic RiskNCT05333328 · 2023-02-06

Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast CancerNCT05982093 · 2023-02-03

Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)NCT05660083 · 2023-01-12

SNF Platform Study of HR+/ HER2-advanced Breast CancerNCT05594095 · 2022-12-30

Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant TherapyNCT05582499 · 2022-11-01

Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer PatientsNCT05452213 · 2022-10-12

Role of the Immune Environment in Response to Therapy in Breast CancerNCT05396612 · 2022-10-03

Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast CancerNCT05467891 · 2022-09-13

Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast CancerNCT05524584 · 2022-08-31

DecipHER Trial - DC1 Tx for Early-Stage TNBC and ER Low Positive Breast CancerNCT05504707 · 2022-08-26

CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast CancerNCT05029999 · 2022-04-20

A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast CancerNCT04985266 · 2022-03-30

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast CancerNCT05216432 · 2021-12-08

Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast CancerNCT05305924 · 2021-02-25

SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem CellsNCT04150042 · 2021-01-13

To Identify Primary Resistance to CDK4/6 Inhibitors in Breast CancerNCT04660435 · 2020-12-01

Clinical Study of Breast Conserving Surgery Combined With Intraoperative Radiotherapy for Early Breast CancerNCT06375798 · 2020-11-19

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)NCT04585750 · 2020-10-29

Efficacy and Safety of Dose-dense Chemotherapy (ddEC-ddP) for Neoadjuvant Chemotherapy of HER2-negative Breast CancerNCT04576143 · 2020-09-20

Sacituzumab Govitecan In TNBCNCT04230109 · 2020-07-14

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerNCT01042379 · 2010-03-01

Study of Multi-mode Thermal Therapy Combined With Immunotherapy In Patients With HER2-negative Breast Cancer With Liver MetastasesNCT07466927 · 2026-03-15

NOT_YET_RECRUITING

Pilot Study of Neoadjuvant Chemotherapy Combined With Immunotherapy and Multimodal Thermal Therapy for HER2-negative Breast CancerNCT06636591 · 2024-12-23

Improvement of Quality of Life Through Supportive Treatments for Hormone Therapy - Related Symptoms in Patients With Early Breast CancerNCT06407401 · 2024-12-01

NOT_YET_RECRUITING

Immunologic Targeting of ESR1 Receptor for Hormone Receptor Expressing Metastatic Breast CancerNCT06691035 · 2024-11-04

ACTIVE_NOT_RECRUITING

A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast CancerNCT06568692 · 2024-10-02

ZAP-IT: ZN-c3 + Carboplatin + Pembrolizumab in mTNBCNCT06351332 · 2024-05-01

BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and Other Advanced Solid TumorsNCT06253195 · 2024-04-01

New Digital Person-based Care Model in Patients With HER2-negative Advanced Breast CancerNCT06348654 · 2024-03-30

Common interventions

Leading sponsors

Fudan University7 National Cancer Institute (NCI)5 BeOne Medicines3 Memorial Sloan Kettering Cancer Center3 University of Washington3 Abramson Cancer Center at Penn Medicine2 Ana C Garrido-Castro, MD2 Barbara Ann Karmanos Cancer Institute2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences2 Dana-Farber Cancer Institute2 Emory University2 European Organisation for Research and Treatment of Cancer - EORTC2 H. Lee Moffitt Cancer Center and Research Institute2 Institut fuer Frauengesundheit2 Jennifer Lee Caswell-Jin2

Trial status mix

RECRUITING52

COMPLETED34

TERMINATED18

ACTIVE_NOT_RECRUITING15

UNKNOWN14

NOT_YET_RECRUITING2

WITHDRAWN2

SUSPENDED1

Phase mix

PHASE275

PHASE141

PHASE311

NA6

PHASE43

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.